Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls

Purpose Our previous high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry study identified bladder cancer (BCA)-specific urine metabolites, including carnitine, acylcarnitines, and melatonin. The objective of the current study was to determine which metabolic pathways are perturbed in BCA, based on our previously identified urinary metabolome. Materials and Methods A total of 135 primary BCA samples and 26 control tissue samples from healthy volunteers were analyzed. The association between specific urinary metabolites and their related encoding genes was analyzed. Results Significant alterations in the carnitine-acylcarnitine and tryptophan metabolic pathways were detected in urine specimens from BCA patients compared to those of healthy controls. The expression of eight genes involved in the carnitine-acylcarnitine metabolic pathway (CPT1A, CPT1B, CPT1C, CPT2, SLC25A20, and CRAT) or tryptophan metabolism (TPH1 and IDO1) was assessed by RT-PCR in our BCA cohort (n=135). CPT1B, CPT1C, SLC25A20, CRAT, TPH1, and IOD1 were significantly downregulated in tumor tissues compared to normal bladder tissues (p<0.05 all) of patients with non-muscle invasive BCA, whereas CPT1B, CPT1C, CRAT, and TPH1 were downregulated in those with muscle invasive BCA (p<0.05), with no changes in IDO1 expression. Conclusion Alterations in the expression of genes associated with the carnitine-acylcarnitine and tryptophan metabolic pathways, which were the most perturbed pathways in BCA, were determined.

• Publication year

  2016

• Venue

  Yonsei medical journal

• Publication date

  2016-05-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3349/ymj.2016.57.4.865PMID 27189278PMCID 4951461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

  2017cited by this paper
• Diagnosis of bladder cancer and prediction of survival by urinary metabolomics

  2014cited by this paper
• 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder.

  2014cited by this paper
• Epidemiology and risk factors of urothelial bladder cancer.

  2013cited by this paper
• Low- and high-grade bladder cancer determination via human serum-based metabolomics approach.

  2013cited by this paper
• Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.

  2013influential reference
• HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.

  2013cited by this paper
• Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease.

  2013cited by this paper
• Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.

  2013influential reference
• Modern nutrition in health and disease: Eleventh edition

  2012cited by this paper
• Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach*

  2011cited by this paper
• Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis

  2011cited by this paper
• Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.

  2011influential reference
• Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe.

  2011cited by this paper
• Differential toxicological effects induced by mercury in gills from three pedigrees of Manila clam Ruditapes philippinarum by NMR-based metabolomics

  2010cited by this paper
• Identification of C16orf74 as a Marker of Progression in Primary Non-Muscle Invasive Bladder Cancer

  2010cited by this paper
• A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.

  2009cited by this paper
• Reply to Anna Orsola, Lluís Cecchini and Juan Morote's Letter to the Editor re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303–14

  2009cited by this paper
• Biology of urothelial tumorigenesis: insights from genetically engineered mice

  2009influential reference
• Strategies for molecular expression profiling in bladder cancer

  2009cited by this paper
• EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.

  2008cited by this paper
• Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison

  2008cited by this paper
• Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions.

  2007cited by this paper
• p53 Regulates Mitochondrial Respiration

  2006cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

  2005cited by this paper
• Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.

  2003cited by this paper
• Crystal structure of carnitine acetyltransferase and implications for the catalytic mechanism and fatty acid transport.

  2003cited by this paper
• The American Joint Committee on Cancer: updating the strategies in cancer staging.

  2002cited by this paper
• Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma

  2001cited by this paper
• Conformation of the substrate and pterin cofactor bound to human tryptophan hydroxylase. Important role of Phe313 in substrate specificity.

  2001cited by this paper
• Genomics of the human carnitine acyltransferase genes.

  2000cited by this paper
• Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12-->p11 by fluorescent in situ hybridization.

  1993cited by this paper
• Carnitine.

  1988cited by this paper
• Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria.

  1984cited by this paper
• The role of urinary tryptophan metabolites in the etiology of bladder cancer.

  1971cited by this paper
• Modern Nutrition in Health and Disease

  1965cited by this paper
• Modern Nutrition In Health And Disease

  1956cited by this paper

• A Comparative Metabolomics Study of Multiple Urological Diseases by Highly Sensitive Dansylation Isotope Labeling LC-MS

  2025cites this paper
• Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer

  2025cites this paper
• An NMR Metabolomics Analysis Pipeline for Human Neutrophil Samples with Limited Source Material

  2025cites this paper
• TPH1 inhibits bladder tumorigenesis by targeting HIF-1α pathway in bladder cancer

  2024cites this paper
• The YY1-CPT1C signaling axis modulates the proliferation and metabolism of pancreatic tumor cells under hypoxia.

  2024cites this paper
• To be or not to be a fat burner, that is the question for cpt1c in cancer cells

  2023cites this paper
• Aberrant Lipid Metabolism in Cancer: Current Status and Emerging Therapeutic Perspectives.

  2023cites this paper
• Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort

  2023cites this paper
• Heterogeneous MXene Hybrid-Oriented Exosome Isolation and Metabolic Profiling for Early Screening, Subtyping and Follow-up Evaluation of Bladder Cancer.

  2023cites this paper
• Metabolomics for the diagnosis of bladder cancer: A systematic review

  2023cites this paper
• Clinical Significance of Carnitine in the Treatment of Cancer: From Traffic to the Regulation

  2023cites this paper
• Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy

  2022cites this paper
• Rapid screening for genitourinary cancers: mass spectrometry-based metabolic fingerprinting of urine.

  2022cites this paper
• Targeting Energy Metabolism in Cancer Treatment

  2022cites this paper
• Metabolic Flexibility in Canine Mammary Tumors: Implications of the Carnitine System

  2021cites this paper
• Urinary Metabolic Biomarkers in Cancer Patients: An Overview.

  2021cites this paper
• Analysis of Nuclear Encoded Mitochondrial Gene Networks in Cervical Cancer

  2021cites this paper
• Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients

  2021cites this paper
• A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma

  2021cites this paper
• Functional Analysis of the Oncogene Carnitine Palmitoyltransferase 1C and Its Regulation under Hypoxia

  2021cites this paper
• Diagnostic Performance of Novel Urine-Based mRNA Tests (Xpert and Urinary Metabolomics Markers Assay) for Bladder Cancer Detection in Patients with Hematuria

  2020cites this paper
• Telomerase Reverse Transcriptase and miR-34a in diagnosis of non-muscle invasive bladder cancer

  2020influential citation
• The role and function of PPARγ in bladder cancer

  2020cites this paper
• Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML

  2020cites this paper
• A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis

  2020cites this paper
• Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers

  2020influential citation
• Carnitine Traffic in Cells. Link With Cancer

  2020cites this paper
• The emerging role of targeting cancer metabolism for cancer therapy

  2020cites this paper
• Non-Coding and Regulatory RNAs as Epigenetic Remodelers of Fatty Acid Homeostasis in Cancer

  2020influential citation
• Multiple Myeloma and Fatty Acid Metabolism

  2019cites this paper
• Structure Annotation of All Mass Spectra in Untargeted Metabolomics.

  2019cites this paper
• Synergistic activation of mitochondrial metabolism and the glutathione redox couple protects HepG2 hepatocarcinoma cells from palmitoylcarnitine-induced stress.

  2019cites this paper
• Characterisation of the Urinary Metabolic Profile of Liver Fluke-Associated Cholangiocarcinoma

  2019cites this paper
• Recognition of early and late stages of bladder cancer using metabolites and machine learning

  2019cites this paper
• Integrative Analysis of Genomic and Clinical Data Reveals Intrinsic Characteristics of Bladder Urothelial Carcinoma Progression

  2019cites this paper
• When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance

  2018cites this paper
• The carnitine system and cancer metabolic plasticity

  2018cites this paper
• Discovering biomarkers in bladder cancer by metabolomics.

  2018cites this paper
• Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery

  2018cites this paper
• Expression and putative role of mitochondrial transport proteins in cancer.

  2017cites this paper
• Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer

  2017cites this paper
• How interacting pathways are regulated by miRNAs in breast cancer subtypes

  2016cites this paper